Aditya Samal, MD
Cardiovascular Disease · Houston, TXNPI 1790744399
Payments from drug & device makers
Across 1,219 payments — averaging $2110.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$977K
- Novo Nordisk AS$864K
- Novartis$479K
- Amgen$245K
- Abbott$3K
- Boston Scientific$963
- plus $4K from 27 others
Across 5 payments — averaging $22,450 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$112K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 15 | $976,675 |
| Novo Nordisk AS | 819 | $864,022 |
| Novartis | 64 | $478,624 |
| Amgen | 39 | $245,168 |
| Abbott | 59 | $3,396 |
| Boston Scientific | 27 | $963 |
| Actelion Pharmaceuticals US, Inc. | 32 | $827 |
| Johnson & Johnson | 28 | $475 |
| AstraZeneca | 20 | $396 |
| E.r. Squibb & Sons, L.L.C. | 21 | $363 |
| Merck | 17 | $354 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 26 | $339 |
| Bard Peripheral Vascular, Inc. | 2 | $219 |
| Biotronik Inc. | 6 | $209 |
| Pfizer | 8 | $187 |
| Amarin Pharma, Inc. | 5 | $97 |
| Boehringer Ingelheim | 3 | $70 |
| Sanofi-aventis U.S. LLC | 3 | $67 |
| Arbor Pharmaceuticals, Inc. | 4 | $59 |
| Tactile Systems Technology Inc | 3 | $57 |
| Bridgebio Pharma, Inc. | 1 | $49 |
| Esperion Therapeutics, Inc. | 2 | $46 |
| Vifor Pharma, Inc. | 2 | $44 |
| Medtronic | 1 | $42 |
| Vital Connect, Inc | 1 | $42 |
| Bayer | 2 | $41 |
| Teleflex LLC | 2 | $41 |
| Scpharmaceuticals Inc. | 2 | $33 |
| Shockwave Medical, Inc | 1 | $31 |
| Braemar Manufacturing, LLC | 1 | $22 |
| Preventice Services, LLC | 1 | $18 |
| Elutia, Inc. | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
How this compares
$2,573,003 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Houston
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- James FeldmanHouston$3.1M
- Pranav LoyalkaHouston$2.4M
- Anwar AhmadHouston$1.4M
- Reynolds DelgadoHouston$1.1M
- Richard SmallingHouston$908K
- Amin KarimHouston$853K
- Stephen LittleHouston$806K
- Joggy GeorgeHouston$634K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.